XML 161 R80.htm IDEA: XBRL DOCUMENT
v3.26.1

Schedule of details of associates (Details) | 12 Months Ended
--- | ---
Mar. 31, 2026 | Mar. 31, 2025
Vax Biotech Sdn Bhd [member] |  |
IfrsStatementLineItems [Line Items] |  |
Place of incorporation | Malaysia |
Effective equity interest |  | 30.00%
Principal activities | Manufacture of medicaments |
Alps Globemedics Sdn Bhd [member] |  |
IfrsStatementLineItems [Line Items] |  |
Place of incorporation | Malaysia |
Effective equity interest | 30.00% | 30.00%
Principal activities | Marketing of health and beauty product and services |
Cilo Cybin Holdings Limited [member] |  |
IfrsStatementLineItems [Line Items] |  |
Place of incorporation | South Africa |
Effective equity interest |  | 40.50%
Principal activities | Investment in biotech, biohacking and pharmaceutical businesses |

X
- References No definition available. + Details
Name: | ALPS_IfrsStatementLineItems
Namespace Prefix: | ALPS_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The country in which the entity is incorporated. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph B18 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B18_a&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 141 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 138 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_138_a&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_CountryOfIncorporation
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the nature of the entity's operations and principal activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 141 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_b&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph B18 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B18_b&doctype=Appendix&subtype=B -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 138 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_138_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2025-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=ALPS_VaxBiotechSdnBhdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=ALPS_AlpsGlobemedicsSdnBhdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=ALPS_CiloCybinHoldingsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |